TABLE 4.
Multiple electrode aggregometry analysis according to study group and healthy controls and patients with end‐stage kidney disease and healthy controls after excluding the patients on antiplatelets medications. Data are expressed as median (IQR). Normal ranges for each test are presented in the left‐hand column
| Study group (n = 103) | Healthy Controls (n = 29) | P | ESKD (n = 28) | Healthy Controls (n = 29) | P | |
|---|---|---|---|---|---|---|
| ADP test 57–113 AU | 50 (28, 70) | 61 (41, 78) | .13 | 37 (20, 61) | 61 (41, 78) | .005 |
| Study group (n = 74) | Healthy controls (n = 30) | P | ESKD (n = 41) | Healthy controls (n = 30) | P | |
|---|---|---|---|---|---|---|
| ASPI test 71–115 AU | 87 (58, 103) | 75 (56, 89) | .07 | 64 (48, 100) | 75 (56, 89) | .976 |
| Study group (n = 120) | Healthy controls (n = 30) | P | ESKD (n = 31) | Healthy controls (n = 30) | P | |
|---|---|---|---|---|---|---|
| TRAP test 84–128 AU | 92 (67, 120) | 112 (84, 121) | .16 | 78 (55, 115) | 112 (84, 121) | .011 |
Abbreviations: ADP, adenosine diphosphate; ASPI, aspirin; ESKD, end‐stage kidney disease; TRAP, thrombin receptor activating peptide.